Art. -Nr.: HY-N0541

Pseudoginsenoside F11

(Synonyms: Ginsenoside A1)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Pseudoginsenoside F11 is an orally active neuroprotective agent. Pseudoginsenoside F11 reduces the expression of β-amyloid precursor protein, inhibits the production of Aβ_1-40, downregulates the expression of JNK2, p53 and activated Caspase 3, and restores the activities of SOD and Glutathione peroxidase. Pseudoginsenoside F11 inhibits the excessive activation of μ-Calpain and restores the level of neuronal Nitric oxide synthase. Pseudoginsenoside F11 reduces infarct volume, alleviates cerebral edema, decreases neuronal loss, improves neurological deficits and enhances long-term functional outcomes in transient cerebral ischemia models. Pseudoginsenoside F11 antagonizes Methamphetamine-induced behavioral deficits, dopamine level reduction and neurotoxicity without altering the baseline behaviors of normal mice. Pseudoginsenoside F11 can be used in studies related to Alzheimer's disease, transient cerebral ischemic injury and Methamphetamine-induced neurotoxicity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.87%
CAS. Nr.: 69884-00-0
Formel: C₄₂H₇₂O₁₄
Molecular Weight:801.01

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Pseudoginsenoside F11 Chemical Structure

CAS. Nr.: 69884-00-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

JNK2

Caspase 3

Alle JNK Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen :

GPX1
GPX4

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

In Vitro

Pseudoginsenoside F11 (10-100 μM; 2 h pre-treatment; 0-24 h OGD/R) protects cultured primary cortical neurons against OGD/R-induced injury by increasing cell viability, restoring neurite structure, maintaining calcium homeostasis, replenishing ATP levels, inhibiting μ-Calpain-mediated α-Fodrin cleavage, reversing deficits in NMDA receptor subunits/PSD95/nNOS, and alleviating endoplasmic reticulum stress, with the most robust effects observed at 100 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pseudoginsenoside F11 (0.32-8 mg/kg; p.o.; daily; 15 days) significantly mitigates Aβ₁-4₂-induced learning and memory impairment in KM mice, with the 8 mg/kg dose showing robust improvement across both Morris water maze and step-through tests^[1].
Pseudoginsenoside F11 (8 mg/kg; p.o.; daily; 28 days) significantly improves learning and memory deficits in APP/PS1 mice, mediated by reduced amyloidogenesis, restored antioxidant function, reduced neuronal apoptosis, and improved neuronal histopathology^[1].
Pseudoginsenoside F11 (12 mg/kg; i.v.; single dose, 0-8 hours post-reperfusion; 3-12 mg/kg; i.v. initial dose, i.p. daily; 14 days) produces dose-dependent neuroprotection in transient cerebral ischemia-reperfusion injured rats, reducing acute brain damage by up to 48.1% infarct volume reduction with a 4-hour therapeutic window, improving long-term survival by 13.6% at 12 mg/kg, and restoring motor function and neuronal health via repression of sustained calcium overload^[2].
Pseudoginsenoside F11 (4-8 mg/kg; p.o.; two times at 4-hour intervals) significantly protects against methamphetamine-induced behavioral neurotoxicities (anxiety, despair, memory impairment) and partially reverses methamphetamine-induced brain dopamine depletion in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

KM mice (male, 6-8 week-old, Alzheimer's disease model via intracerebroventricular injection of 410 pmol Aβ₁-4₂)^[1]
Dosage:

0.32 mg/kg; 1.6 mg/kg; 8 mg/kg
Administration:

p.o.; daily; 15 days
Result:

Significantly reduced Aβ₁-4₂-induced increases in escape latency (p < 0.05 on days 3, 4, and 5 of place navigation testing) and escape distance (p < 0.05 on day 5 of place navigation testing) at 8 mg/kg.
Restored reduced time spent in the target quadrant (p = 0.004) in the Morris water maze probe test and blocked reduced step-through latency in the retention trial (p = 0.026) at 8 mg/kg.
Reduced escape latency on day 3 of place navigation testing (p < 0.05) and restored reduced time spent in the target quadrant (p = 0.011) in the probe test at 1.6 mg/kg.
Showed no significant effects on swim velocity across all doses.

Animal Model:

Swiss mice (male, 7-week-old, 20-22 g, methamphetamine-induced neurotoxicity model)^[3]
Dosage:

4 mg/kg; 8 mg/kg
Administration:

p.o.; two times at 4-hour intervals
Result:

Shortened methamphetamine-induced prolonged time spent in the dark box in the light-dark box task.
Reversed methamphetamine-induced prolonged immobility time in the forced swimming task.
Shortened methamphetamine-induced prolonged latency to find food and reduced the number of errors in the appetitively motivated T-maze task.
Shortened methamphetamine-induced prolonged escape latency to locate the hidden platform across test days in the Morris water maze task.
Partially but significantly antagonized the methamphetamine-induced decrease in brain dopamine (DA) content, with a 23.22% recovery of DA levels.
Showed no significant effect on methamphetamine-induced decreases in 3,4-dihydroxyphenacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindoacetic acid (5-HIAA), or 5-hydroxytryptamine (5-HT) contents.
Affected neither swimming ability, spontaneous behavior, nor baseline levels of brain monoamines and their metabolites in non-methamphetamine-treated mice.

Chemical Information

CAS. Nr. 69884-00-0
Appearance Solid
Molecular Weight 801.01
Formel C₄₂H₇₂O₁₄
Color White to light yellow
SMILES

C[C@@]([C@@]12C)(C[C@H](O[C@@](O[C@H](CO)[C@@H](O)[C@@H]3O)([H])[C@@H]3O[C@@](O[C@@H](C)[C@H](O)[C@H]4O)([H])[C@@H]4O)[C@@]5([H])C6(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@]7(O[C@@H](C(C)(O)C)CC7)C)([H])CC2)([H])[C@]5(CC[C@@H]6O)C
Synonyms

Ginsenoside A1
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (2)

All

Sort by:

Journal Impact Factor

Phytomedicine

Pseudoginsenoside F11 enhances YBX1-mediated transcriptional repression of PRPS2 to inhibit the stemness and pulmonary metastasis of triple- negative breast cancer. [Abstract]

2026 Jun:155:158064. PMID: 41855762
Front Pharmacol

Pseudoginsenoside F11 Enhances the Viability of Random-Pattern Skin Flaps by Promoting TFEB Nuclear Translocation Through AMPK-mTOR Signal Pathway. [Abstract]

2021 Apr 29:12:667524. PMID: 33995096

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (62.42 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 0.67 mg/mL (0.84 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2484 mL

6.2421 mL

12.4842 mL

5 mM

0.2497 mL

1.2484 mL

2.4968 mL

10 mM

0.1248 mL

0.6242 mL

1.2484 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wang CM, et al. Anti-amnesic effect of pseudoginsenoside-F11 in two mouse models of Alzheimer's disease. Pharmacol Biochem Behav. 2013;106:57-67. [Content Brief]

[2]. Zhang T, et al. Pseudoginsenoside-F11 Protects against Transient Cerebral Ischemia Injury in Rats Involving Repressing Calcium Overload. Neuroscience. 2019;411:86-104. [Content Brief]

[3]. Wu CF, et al. Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice. Pharmacol Biochem Behav. 2003;76(1):103-109. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2484 mL	6.2421 mL	12.4842 mL	31.2106 mL
	5 mM	0.2497 mL	1.2484 mL	2.4968 mL	6.2421 mL
	10 mM	0.1248 mL	0.6242 mL	1.2484 mL	3.1211 mL
	15 mM	0.0832 mL	0.4161 mL	0.8323 mL	2.0807 mL
	20 mM	0.0624 mL	0.3121 mL	0.6242 mL	1.5605 mL
	25 mM	0.0499 mL	0.2497 mL	0.4994 mL	1.2484 mL
	30 mM	0.0416 mL	0.2081 mL	0.4161 mL	1.0404 mL
	40 mM	0.0312 mL	0.1561 mL	0.3121 mL	0.7803 mL
	50 mM	0.0250 mL	0.1248 mL	0.2497 mL	0.6242 mL
	60 mM	0.0208 mL	0.1040 mL	0.2081 mL	0.5202 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Pseudoginsenoside F11

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Pseudoginsenoside F11

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Cuproptosis Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Pseudoginsenoside F11

Alle JNK Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Pseudoginsenoside F11 Related Classifications

Art. -Nr.: HY-N0541